Business Context and Reporting Period
This Form 8-K, dated April 12, 2019, reports the completion of a reverse merger transaction by Vital Therapies, Inc. (now Immunic, Inc.). On the Closing Date, Immunic AG became a wholly-owned subsidiary of the Company through an exchange of shares. Concurrently, the Company changed its name to Immunic, Inc., executed a 40:1 reverse stock split, and changed its trading symbol from "VTL" to "IMUX" on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Transaction Consideration: 8,927,130 shares of Company common stock were issued to Immunic shareholders (post-reverse split).
- Ownership Structure: Post-transaction, former Immunic shareholders own approximately 88.25% of the Company, while former Vital Therapies shareholders own approximately 11.75%.
- Exchange Ratio: Each Immunic ordinary share was converted into the right to receive 17.17 shares of Company common stock (post-reverse split).
- Recent Financing: Prior to the transaction, Immunic raised approximately $30 million (€26,677,176) via a private placement of 129,744 ordinary shares.
- Financial Statements: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period. Pro forma financial information is scheduled to be filed within 71 calendar days.
Material Changes Versus Prior Period
- Corporate Identity: The registrant changed its name from Vital Therapies, Inc. to Immunic, Inc.
- Capital Structure: A 40:1 reverse stock split was effected, and the CUSIP number was updated to 4525EP 101.
- Accounting Firm: PricewaterhouseCoopers LLP (PwC) was dismissed as the independent registered public accounting firm. PwC's 2018 report included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern. Baker Tilly Virchow Krause, LLP was appointed as the new auditor.
- Management and Board: The entire prior board and executive team resigned. A new board of five directors and a new executive team were appointed, led by Dr. Daniel Vitt as CEO.
Guidance, Outlook, and Risks
- Lock-Up Agreements: Former Immunic shareholders, executive officers, and directors have entered into lock-up agreements prohibiting the sale or transfer of securities for 180 days following the Closing Date.
- Going Concern History: The filing notes that the previous auditor (PwC) expressed substantial doubt about the Company's ability to continue as a going concern in its 2018 report. The filing does not explicitly state if this condition has been resolved, though the transaction and recent financing suggest a change in capital position.
- Future Filings: The Company intends to file required financial statements of the acquired business and pro forma financial information in an amendment to this report within 71 days.
Investor Verification Checklist
- Verify the pro forma financial statements to be filed within 71 days to assess the combined entity's liquidity and going concern status.
- Confirm the exact number of shares outstanding post-transaction and the impact of the 40:1 reverse split on share price.
- Review the Investment and Subscription Agreement (Exhibit 10.1) for details on the $30 million financing terms.
- Monitor the 180-day lock-up expiration date for potential selling pressure from former Immunic shareholders.
- Assess the strategic rationale for the merger and the new management team's track record in the biopharmaceutical sector.